David Lewin, Ph.D.
David A. Lewin, Ph.D., has over nine years of licensing and marketing experience in life sciences—eight at OCR—and has spent over 15 years successfully managing scientific-based business alliances with pharmaceutical leaders in the U.S., Europe and Japan. He has demonstrated scientific expertise in: pharmaceuticals, biomarkers, cell biology, genomics and proteomics in many disease areas as well as successful clinical biomarker discovery, development, validation and clinical implementation. Dave has been instrumental in establishing new ventures at OCR, including Kolltan Pharmaceuticals, NovaTract, Eli Nutrition, BioHaven Pharmaceuticals and Kleo Pharmaceuticals. Prior to his work at OCR, Dave was a group leader for CuraGen Corporation in Collaborative Research/Alliance Management and Biomarkers Discovery and Development.
Dave holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego and a Ph.D. in Cell Biology from Yale (Mellman Lab).